Literature DB >> 19808652

Correlation of CXCL12 expression and FoxP3+ cell infiltration with human papillomavirus infection and clinicopathological progression of cervical cancer.

Fatimah Jaafar1, Elda Righi, Victoria Lindstrom, Christine Linton, Mahrokh Nohadani, Susan Van Noorden, Tyler Lloyd, Joshua Poznansky, Gordon Stamp, Roberto Dina, Dulcie V Coleman, Mark C Poznansky.   

Abstract

Human cervical cancer is an immunogenic tumor with a defined pattern of histopathological and clinical progression. Tumor-infiltrating T cells contribute to immune control of this tumor; however, cervical cancer dysregulates this immune response both through its association with human papillomavirus (HPV) infection and by producing cytokines and chemokines. Animal tumor models have revealed associations between overproduction of the chemokine stromal cell-derived factor-1 (SDF-1 or CXCL12) and dysregulation of tumor-specific immunity. We therefore proposed that CXCL12 expression by cervical precancerous and cancerous lesions correlates with histopathological progression, loss of immune control of the tumor, and HPV infection. We found a significant association between cancer stage and CXCL12 expression for squamous and glandular lesions as well as with the HPV16+ (high-risk) status of the neoplastic lesions. Cancer progression was correlated with increasing levels of FoxP3 T-cell infiltration in the tumor. FoxP3 and CXCL12 expression significantly correlated for squamous and glandular neoplastic lesions. These observations were supported by enzyme-linked immunosorbent assay and Western blotting. In addition, we demonstrated CXCL12 expression by dyskaryotic cells in ThinPrep cervical smears. This study robustly links increased CXCL12 expression and FoxP3(+)-cell infiltration to HPV infection and progression of cervical cancer. It supports the detection of CXCL12 in cervical smears and biopsies as an additional biomarker for this disease.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19808652      PMCID: PMC2751549          DOI: 10.2353/ajpath.2009.090295

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  32 in total

1.  Active movement of T cells away from a chemokine.

Authors:  M C Poznansky; I T Olszak; R Foxall; R H Evans; A D Luster; D T Scadden
Journal:  Nat Med       Date:  2000-05       Impact factor: 53.440

Review 2.  The cell-mediated immune response to human papillomavirus-induced cervical cancer: implications for immunotherapy.

Authors:  Gretchen L Eiben; Markwin P Velders; W Martin Kast
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

Review 3.  The T-cell response in patients with cancer.

Authors:  Chiara Castelli; Markus J Maeurer
Journal:  Adv Cancer Res       Date:  2002       Impact factor: 6.242

4.  Involvement of chemokine receptors in breast cancer metastasis.

Authors:  A Müller; B Homey; H Soto; N Ge; D Catron; M E Buchanan; T McClanahan; E Murphy; W Yuan; S N Wagner; J L Barrera; A Mohar; E Verástegui; A Zlotnik
Journal:  Nature       Date:  2001-03-01       Impact factor: 49.962

Review 5.  Novel immunotherapeutic strategies in gynecologic oncology. Dendritic cell-based immunotherapy for ovarian cancer.

Authors:  A D Santin; S Bellone; L J Underwood; T J O'Brien; A Ravaggi; S Pecorelli; M J Cannon
Journal:  Minerva Ginecol       Date:  2002-04

6.  Stromal-derived factor-1 in human tumors recruits and alters the function of plasmacytoid precursor dendritic cells.

Authors:  W Zou; V Machelon; A Coulomb-L'Hermin; J Borvak; F Nome; T Isaeva; S Wei; R Krzysiek; I Durand-Gasselin; A Gordon; T Pustilnik; D T Curiel; P Galanaud; F Capron; D Emilie; T J Curiel
Journal:  Nat Med       Date:  2001-12       Impact factor: 53.440

7.  Multiple actions of the chemokine CXCL12 on epithelial tumor cells in human ovarian cancer.

Authors:  Chris J Scotton; Julia L Wilson; Kate Scott; Gordon Stamp; George D Wilbanks; Simon Fricker; Gary Bridger; Frances R Balkwill
Journal:  Cancer Res       Date:  2002-10-15       Impact factor: 12.701

8.  Efficacious immunomodulatory activity of the chemokine stromal cell-derived factor 1 (SDF-1): local secretion of SDF-1 at the tumor site serves as T-cell chemoattractant and mediates T-cell-dependent antitumor responses.

Authors:  Kyriaki Dunussi-Joannopoulos; Krystyna Zuberek; Kathlene Runyon; Robert G Hawley; Anthony Wong; Jamie Erickson; Steve Herrmann; John P Leonard
Journal:  Blood       Date:  2002-09-01       Impact factor: 22.113

Review 9.  Immunological treatment of ovarian cancer.

Authors:  Martin J Cannon; Alessandro D Santin; Timothy J O'Brien
Journal:  Curr Opin Obstet Gynecol       Date:  2004-02       Impact factor: 1.927

10.  Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss.

Authors:  Blaise Clarke; Anna V Tinker; Cheng-Han Lee; Subbaya Subramanian; Matt van de Rijn; Dmitry Turbin; Steve Kalloger; Guangming Han; Kathy Ceballos; Mark G Cadungog; David G Huntsman; George Coukos; C Blake Gilks
Journal:  Mod Pathol       Date:  2008-12-05       Impact factor: 7.842

View more
  34 in total

Review 1.  Roles of regulatory T cells in cancer immunity.

Authors:  Yoshiko Takeuchi; Hiroyoshi Nishikawa
Journal:  Int Immunol       Date:  2016-05-09       Impact factor: 4.823

2.  FOXP3 autoantibody as a potential early prognostic serum biomarker in patients with cervical cancer.

Authors:  Shuang Xu; Mingmei Huangfu; Xueli Jia; Xiaowei Song; Baosheng Sun; Kuang-Hui Lee; Linlin Liu; Shilong Sun
Journal:  Int J Clin Oncol       Date:  2015-02-15       Impact factor: 3.402

Review 3.  Premetastatic milieu explained by TLR4 agonist-mediated homeostatic inflammation.

Authors:  Yoshiro Maru
Journal:  Cell Mol Immunol       Date:  2010-02-08       Impact factor: 11.530

4.  CXCL12/CXCR4 blockade induces multimodal antitumor effects that prolong survival in an immunocompetent mouse model of ovarian cancer.

Authors:  Elda Righi; Satoshi Kashiwagi; Jianping Yuan; Michael Santosuosso; Pierre Leblanc; Rachel Ingraham; Benjamin Forbes; Beth Edelblute; Brian Collette; Deyin Xing; Magdalena Kowalski; Maria Cristina Mingari; Fabrizio Vianello; Michael Birrer; Sandra Orsulic; Glenn Dranoff; Mark C Poznansky
Journal:  Cancer Res       Date:  2011-07-08       Impact factor: 12.701

5.  Pathologic and imunohistochemical characterization of tumoral inflammatory cell infiltrate in invasive penile squamous cell carcinomas: Fox-P3 expression is an independent predictor of recurrence.

Authors:  José Vassallo; André Fellipe Freitas Rodrigues; Antonio Hugo J F M Campos; Rafael Malagoli Rocha; Isabela Werneck da Cunha; Stênio Cássio Zequi; Gustavo Cardoso Guimarães; Francisco Paulo da Fonseca; Ademar Lopes; Antonio Cubilla; Fernando Augusto Soares
Journal:  Tumour Biol       Date:  2015-01-05

6.  Angiotensin II induces calcium/calcineurin signaling and podocyte injury by downregulating microRNA-30 family members.

Authors:  Yue Zhao; Junnan Wu; Mingchao Zhang; Minlin Zhou; Feng Xu; Xiaodong Zhu; Xianguang Zhou; Yue Lang; Fan Yang; Shifeng Yun; Shaolin Shi; Zhihong Liu
Journal:  J Mol Med (Berl)       Date:  2017-05-24       Impact factor: 4.599

Review 7.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  CXCL12 is a key regulator in tumor microenvironment of cervical cancer: an in vitro study.

Authors:  Suresh Singh Yadav; Shyam Babu Prasad; Chandra Bhushan Prasad; Lakshmi Kant Pandey; Satyajit Pradhan; Sunita Singh; Gopeshwar Narayan
Journal:  Clin Exp Metastasis       Date:  2016-03-12       Impact factor: 5.150

9.  Tumor-infiltrating regulatory T cells: phenotype, role, mechanism of expansion in situ and clinical significance.

Authors:  C Tanchot; M Terme; H Pere; T Tran; N Benhamouda; M Strioga; C Banissi; L Galluzzi; G Kroemer; E Tartour
Journal:  Cancer Microenviron       Date:  2012-10-27

10.  Photon-induced cell migration and integrin expression promoted by DNA integration of HPV16 genome.

Authors:  Stefan Rieken; Florian Simon; Daniel Habermehl; Jan Oliver Dittmar; Stephanie E Combs; Klaus Weber; Jürgen Debus; Katja Lindel
Journal:  Strahlenther Onkol       Date:  2014-03-19       Impact factor: 3.621

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.